Chinese
英语
Sort By排序

共检索7条数据Total:7

2021-06-09

Division of Cardiology Minneapolis Veterans Affairs Health Care System Minneapolis MN.; Department of Medicine University of Minnesota Minneapolis MN.; Cardiac Rhythm Heart FailureMedtronic, Inc Minneapolis MN.; Cardiac Rhythm Heart FailureMedtronic, Inc Minneapolis MN.; Department of Medicine McGovern Medical SchoolUTHealth Houston TX.; Electrophysiology Clinical Research and Innovations Texas Heart Institute Houston TX.; Cardiac Rhythm Heart FailureMedtronic, Inc Minneapolis MN.

Background COVID-19 was temporally associated with an increase in out-of-hospital cardiac arrests, but the underlying mechanisms are unclear. We sought to determine if patients with implantable defibrillators residing in areas with high COVID-19 activity experienced an increase in defibrillator shocks during the COVID-19 outbreak. Methods and Results Using the Medtronic (Mounds View, MN) Carelink database from 2019 and 2020, we retrospectively determined the incidence of implantable defibrillator shock episodes among patients residing in New York City, New Orleans, LA, and Boston, MA. A total of 14 665 patients with a Medtronic implantable defibrillator (age, 66±13 years; and 72% men) were included in the analysis. Comparing analysis time periods coinciding with the COVID-19 outbreak in 2020 with the same periods in 2019, we observed a larger mean rate of defibrillator shock episodes per 1000 patients in New York City (17.8 versus 11.7, respectively), New Orleans (26.4 versus 13.5

2021-09-15

Department of Radiology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Division of Clinical Informatics, Department of Medicine, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.

The continued need for molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the potential for self-collected saliva as an alternative to nasopharyngeal (NP) swabs for sample acquisition led us to compare saliva to NP swabs in an outpatient setting without restrictions to avoid food, drink, smoking, or tooth-brushing. A total of 385 pairs of NP and saliva specimens were obtained, the majority from individuals presenting for initial evaluation, and were tested on two high-sensitivity reverse transcriptase PCR (RT-PCR) platforms, the Abbott m2000 and Abbott Alinity m (both with limits of detection [LoD] of 100 copies of viral RNA/ml). Concordance between saliva and NP swabs was excellent overall (Cohen's κ = 0.93) for both initial and follow-up testing, for both platforms, and for specimens treated with guanidinium transport medium as preservative as well as for untreated saliva (κ = 0.88 to 0.95). Viral loads were on average 16× higher in NP specimens

2021-06-01

Department of Gastroenterology, Wenzhou Central Hospital, Wenzhou, China.; Department of Infectious Disease, Wenzhou Central Hospital, Wenzhou, China.; Department of Thoracic Surgery, Wenzhou Central Hospital, Wenzhou, China.; Department of Infectious Disease, Wenzhou Central Hospital, Wenzhou, China.; Department of Hematology, Wenzhou Key Laboratory of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; Department of Hematology, Wenzhou Key Laboratory of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; Department of Hematology, Wenzhou Key Laboratory of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; Department of Infectious Disease, Wenzhou Central Hospital, Wenzhou, China.; Department of Thoracic Surgery, Wenzhou Central Hospital, Wenzhou, China.; Department of Infectious Disease, Wenzhou Central Hospital, Wenzhou, China.

Background: During the COVID-19 pandemic, many patients admitted to hospital for treatment have recovered and been discharged; however, in some instances, these same patients are re-admitted due to a second fever or a positive COVID-19 PCR test result. To ascertain whether it is necessary to treat these patients in hospitals, especially in asymptomatic cases, we summarize and analyze the clinical and treatment characteristics of patients re-admitted to hospital with a second COVID-19 infection. Methods: Of the 141 COVID-19 cases admitted to the Wenzhou Central Hospital between January 17, 2020, to March 5, 2020, which were followed until March 30, 2020, 12 patients were re-admitted with a second COVID-19 infection. Data was collected and analyzed from their clinical records, lab indexes, commuted tomography (CT), and treatment strategies. Results: Most of the 141 patients had positive outcomes from treatment, with only 12 (8.5%) being re-admitted. In this sub-group: one (8.3%) had a

2021-03-08

Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Pulmonary and Critical Care Medicine, The Third People's Hospital of Yichang, China Three Gorges University Third People's Hospital.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Pulmonary and Critical Care Medicine, The Third People's Hospital of Yichang, China Three Gorges University Third People's Hospital.; Medical Department, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang, Yichang, Hubei, China.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.

Mortality of critically ill patients with coronavirus disease 2019 (COVID-19) was high. Aims to examine whether time from symptoms onset to intensive care unit (ICU) admission affects incidence of extra-pulmonary complications and prognosis in order to provide a new insight for reducing the mortality. A single-centered, retrospective, observational study investigated 45 critically ill patients with COVID-19 hospitalized in ICU of The Third People's Hospital of Yichang from January 17 to March 29, 2020. Patients were divided into 2 groups according to time from symptoms onset to ICU admission (>7 and ≤7 days) and into 2 groups according to prognosis (survivors and non-survivors). Epidemiological, clinical, laboratory, radiological characteristics and treatment data were studied. Compared with patients who admitted to the ICU since symptoms onset ≤7 days (55.6%), patients who admitted to the ICU since symptoms onset >7 days (44.4%) were more likely to have extra-pulmonary complications

2021-08-10

Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Research & Development Strategy & Operations, Amgen, Inc, Thousand Oaks, California, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Center for Observational Research, Amgen, Inc, Thousand Oaks, California, USA.; Data Sciences Institute, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Center for Observational Research and Data Science, Bristol-Myers Squibb, Princeton, New Jersey, USA ying.bao@bms.com.

OBJECTIVE: To examine age, gender, and temporal differences in baseline characteristics and clinical outcomes of adult patients hospitalised with COVID-19. DESIGN: A cohort study using deidentified electronic medical records from a Global Research Network. SETTING/PARTICIPANTS: 67 456 adult patients hospitalised with COVID-19 from the USA; 7306 from Europe, Latin America and Asia-Pacific between February 2020 and January 2021. RESULTS: In the US cohort, compared with patients 18-34 years old, patients ≥65 had a greater risk of intensive care unit (ICU) admission (adjusted HR (aHR) 1.73, 95% CI 1.58 to 1.90), acute respiratory distress syndrome(ARDS)/respiratory failure (aHR 1.86, 95% CI 1.76 to 1.96), invasive mechanical ventilation (IMV, aHR 1.93, 95% CI, 1.73 to 2.15), and all-cause mortality (aHR 5.6, 95% CI 4.36 to 7.18). Men appeared to be at a greater risk for ICU admission (aHR 1.34, 95% CI 1.29 to 1.39), ARDS/respiratory failure (aHR 1.24, 95% CI1.21 to 1.27), IMV (aHR 1.38

12

2020-01-27

Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan; Agricultural University, Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Research Center of Avian Disease, College of Veterinary Medicine, Sichuan; Agricultural University, Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China

Duck plague virus (DPV) is a representative pathogen transmitted among aquatic animals that causes gross lesions and immune inhibition in geese and ducks. The mechanism of organ tropism and innate immune evasion of DPV has not been completely deciphered due to a lack of cell models to study the innate immune manipulation and pathogenicity of aquatic viruses. In the present study, we isolated five types of duck primary cells [duck embryo fibroblasts (DEFs), neurons, astrocytes, peripheral blood mononuclear cells (PBMCs), and monocytes/macrophages] to identify appropriate cell models for DPV, using tropism infection and innate immunologic assays. Cells responded differently to stimulation with DNA viruses or RNA virus analogs. DPV infection exhibited broad tropism, as the recombinant virulent strain (CHv-GFP) infected DEFs, neurons, astrocytes, and monocytes/macrophages, but not the PBMCs, as the expression of EGFP was

2020-01-27

Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan; Agricultural University, Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Research Center of Avian Disease, College of Veterinary Medicine, Sichuan; Agricultural University, Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China Institute of Preventive Veterinary Medicine, Sichuan Agricultural University,; Chengdu, China

Duck plague virus (DPV) is a representative pathogen transmitted among aquatic animals that causes gross lesions and immune inhibition in geese and ducks. The mechanism of organ tropism and innate immune evasion of DPV has not been completely deciphered due to a lack of cell models to study the innate immune manipulation and pathogenicity of aquatic viruses. In the present study, we isolated five types of duck primary cells [duck embryo fibroblasts (DEFs), neurons, astrocytes, peripheral blood mononuclear cells (PBMCs), and monocytes/macrophages] to identify appropriate cell models for DPV, using tropism infection and innate immunologic assays. Cells responded differently to stimulation with DNA viruses or RNA virus analogs. DPV infection exhibited broad tropism, as the recombinant virulent strain (CHv-GFP) infected DEFs, neurons, astrocytes, and monocytes/macrophages, but not the PBMCs, as the expression of EGFP was